Intersect ENT (XENT) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Intersect ENT (XENT) Reports Slight Revenue Miss; Piper Jaffray Cuts Price Target to $23
November 5, 2015 10:00 AM ESTPiper Jaffray maintained an Overweight rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $23.00 (from $30.00), following the company's 3Q earnings report and conference call. XENT reports revenues up 56%, slightly missing consensus of 60%.
Analyst Thomas Gunderson commented, "A slight... More



